Business
PRTC's Lymphatic Platform Candidate Human Study
PRTC's Lymphatic Platform Candidate Human Study.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7519U\n PureTech Health PLC\n 07 December 2021\n \n \n \n \n 7 December 2021\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions\n \n \n \n \n \n LYT-300 is the first candidate from the GlyphTM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech's pipeline \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced today the initiation of a clinical study of LYT-300 (oral allopregnanolone), PureTech's wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 is the third clinical-stage, wholly-owned candidate from PureTech's pipeline. \n \n \n \n \n \n LYT-300 is an oral form of allopregnanolone. Allopregnanolone is a natural neurosteroid that is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, which are known to play a key biological role in depression, epilepsy and other neurological and neuropsychological conditions. Natural allopregnanolone has poor oral bioavailability, thus limiting its development as a therapeutic. An injectable formulation of allopregnanolone is approved by the United States Food and Drug Administration (FDA) as a 60-hour infusion for the treatment of post-partum depression, though the method of administration has limitations. LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.\n \n \n \n \n \n \"Allopregnanolone is a powerful, natural regulator of mood disorders and other neurological conditions, but its therapeutic development has been limited by its poor oral bioavailability. Synthetic oral analogs of allopregnanolone have been developed, though the...